BRAF-mutated metastatic Melanoma: First Results on long-term Efficacy of targeted Therapies

被引：1
|
作者：
Hermann, R. M. [1 ]
Christiansen, H. [2 ]
机构：
[1] Zentrum Strahlentherapie & Radioonkol, Mozartstr 30, D-26655 Westerstede, Germany
[2] Hannover Med Sch, Klin Strahlentherapie & Spezielle Onkol, Hannover, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2019年 / 195卷 / 10期
关键词：
SURVIVAL; IPILIMUMAB;
D O I：
10.1007/s00066-019-01504-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：940 / 942
页数：3
相关论文
共 50 条
  • [11] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [12] Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience
    Sun, Chen
    Espana, Sofia
    Richarz, Nina
    Sole-Blanch, Carme
    Boada, Aram
    Martinez-Cardus, Anna
    Chu, Alan
    Liu, Zongwen
    Manzano, Jose Luis
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [13] Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Schummer, Patrick
    Schilling, Bastian
    Gesierich, Anja
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) : 493 - 504
  • [14] Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence
    Rogala, Pawel
    Czarnecka, Anna M.
    Cybulska-Stopa, Bozena
    Ostaszewski, Krzysztof
    Piejko, Karolina
    Zietek, Marcin
    Dziura, Robert
    Rutkowska, Ewa
    Galus, Lukasz
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Salek-Zan, Agata
    Zemelka, Tomasz
    Bal, Wieslaw
    Kamycka, Agnieszka
    Switaj, Tomasz
    Kaminska-Winciorek, Grazyna
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [15] Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies
    Gambichler, Thilo
    Iordanou, Maria
    Becker, Juergen C.
    Susok, Laura
    MELANOMA RESEARCH, 2024, 34 (01) : 80 - 83
  • [16] Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Patrick Schummer
    Bastian Schilling
    Anja Gesierich
    American Journal of Clinical Dermatology, 2020, 21 : 493 - 504
  • [17] Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients
    Pier Francesco Ferrucci
    Marko Lens
    Emilia Cocorocchio
    Current Oncology Reports, 2021, 23
  • [18] Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients
    Ferrucci, Pier Francesco
    Lens, Marko
    Cocorocchio, Emilia
    CURRENT ONCOLOGY REPORTS, 2021, 23 (12)
  • [19] Targeted Therapy for the Adjuvant Treatment of Stage III BRAF-Mutated Melanoma
    Long, Georgina
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 25 - 27
  • [20] Segmental pityriasis rosea within the area of BRAF-mutated metastatic melanoma
    Murad, A.
    Ralph, N.
    Mulligan, N.
    Moloney, F. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) : E133 - E134
12345